ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.400

+1.7%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jargonweary	7/6/2025 12:07:12 PM
	of 1221

This is good news primarily because it isn’t bad news. By that I mean that approval by GB and Europe surely was expected to happen based on FDA approval and the fact that such approval, I assume, typically foreshadows approval in other markets. Further delay or non-approval would have been very bad for the share price but it is possible that approval has been expected and already factored in to the current share price. I hope that is not true and that we get a nice upward surge in the share price but it is hard to believe that GB and European rejection of Anktiva was what the market expected. In any case it is very good to get this box checked.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next